Literature DB >> 8724671

Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS.

A M Sardar1, C Czudek, G P Reynolds.   

Abstract

We sought to determine whether the motor dysfunctions and neuroleptic sensitivity that can occur in patients with AIDS relates to a deficit of striatal dopamine innervation similar to that of Parkinson's disease. For this purpose we measured concentrations of dopamine and its major metabolite homovanillic acid (HVA) in caudate nucleus tissue taken post-mortem from patients with AIDS and from appropriate age-matched control subjects. Dopamine and HVA concentrations were both significantly reduced in the AIDS group, with 20 of 34 patients exhibiting dopamine concentrations below the control range. This finding is consistent with a loss of nigrostriatal dopaminergic neurones, and may underlie the motor dysfunction and neuroleptic sensitivity that can occur in AIDS patients, indicating the potential value of antiparkinsonian therapy in such patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8724671     DOI: 10.1097/00001756-199603220-00015

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  46 in total

1.  Acceleration of HIV dementia with methamphetamine and cocaine.

Authors:  A Nath; W F Maragos; M J Avison; F A Schmitt; J R Berger
Journal:  J Neurovirol       Date:  2001-02       Impact factor: 2.643

2.  Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses.

Authors:  C Scheller; G Arendt; T Nolting; C Antke; S Sopper; M Maschke; M Obermann; A Angerer; I W Husstedt; F Meisner; E Neuen-Jacob; H W Müller; P Carey; V Ter Meulen; P Riederer; E Koutsilieri
Journal:  J Neural Transm (Vienna)       Date:  2010-05-09       Impact factor: 3.575

3.  Reward, attention, and HIV-related risk in HIV+ individuals.

Authors:  Brian A Anderson; Sharif I Kronemer; Jessica J Rilee; Ned Sacktor; Cherie L Marvel
Journal:  Neurobiol Dis       Date:  2015-10-17       Impact factor: 5.996

4.  Elevated brain monoamine oxidase activity in SIV- and HIV-associated neurological disease.

Authors:  Kelly A Meulendyke; Ceereena Ubaida-Mohien; Julia L Drewes; Zhaohao Liao; Lucio Gama; Kenneth W Witwer; David R Graham; M Christine Zink
Journal:  J Infect Dis       Date:  2014-03-31       Impact factor: 5.226

5.  Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage.

Authors:  Shuxian Hu; Wen S Sheng; James R Lokensgard; Phillip K Peterson; R Bryan Rock
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

6.  Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.

Authors:  Italo Mocchetti; Alessia Bachis; Rachel L Nosheny; Gianluigi Tanda
Journal:  Neurotox Res       Date:  2007-09       Impact factor: 3.911

Review 7.  Amphetamine toxicities: classical and emerging mechanisms.

Authors:  Bryan K Yamamoto; Anna Moszczynska; Gary A Gudelsky
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

8.  Specific infection and destruction of dopaminergic neurons in the substantia nigra by Theiler's virus.

Authors:  K R Oliver; P Brennan; J K Fazakerley
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

9.  [3H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Transactivator of Transcription Protein.

Authors:  Matthew Strauss; Bernadette O'Donovan; Yizhi Ma; Ziyu Xiao; Steven Lin; Michael T Bardo; Pavel I Ortinski; Jay P McLaughlin; Jun Zhu
Journal:  J Pharmacol Exp Ther       Date:  2020-05-27       Impact factor: 4.030

10.  Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains.

Authors:  Adarsh M Kumar; J B Fernandez; Elyse J Singer; Deborah Commins; Drenna Waldrop-Valverde; Raymond L Ownby; Mahendra Kumar
Journal:  J Neurovirol       Date:  2009-05       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.